ArticleOncogene2021
YTHDF2 is a potential target of AML1/ETO-HIF1α loop-mediated cell proliferation in t(8;21) AML.
Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 58 citations in OpenAlex.
- m6A Modification of ATOX1 Inhibits Acute Myeloid Leukemia Progression by Promoting Cuproptosis.Cancer research communications · 2026Article
- Fbxo2 suppresses prostate cancer progression by regulating YTHDF2 ubiquitination and degradation.Cell death & disease · 2025Article
- Article
- Altered Expression of m6A-Associated Genes Is Linked with Poor Prognosis in Pediatric Acute Myeloid Leukemia Patients.Biomolecules · 2025Article
- WTAP-mediated mOncogene · 2025Article
- Phenylpyrazoles as Inhibitors of the mJACS Au · 2025Article
- Review
- Comparative analysis of improved m6A sequencing based on antibody optimization for low-input samples.Scientific reports · 2025Article
- Review
- Metabolic dependencies of acute myeloid leukemia stem cells.International journal of hematology · 2024Review
- Reading the mCell & bioscience · 2024Review
- N6-methyladenosine RNA modifications: a potential therapeutic target for AML.Annals of hematology · 2024Review
- The YTH domain-containing protein family: Emerging players in immunomodulation and tumour immunotherapy targets.Clinical and translational medicine · 2024Review
- Progression of mCell death discovery · 2024Review
- Small molecule inhibitors targeting mJournal of hematology & oncology · 2024Review
- Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy.Cancer medicine · 2024Review
- A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia.Experimental hematology & oncology · 2024Article
- RNA mGenes & diseases · 2024Article
- Current insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects.Frontiers in oncology · 2024Review
- Current Progress of Ferroptosis Study in Hepatocellular Carcinoma.International journal of biological sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The t(8;21) fusion product, AML1/ETO, and hypoxia-inducible factor 1α (HIF1α) form a feed-forward transcription loop that cooperatively transactivates the DNA methyltransferase 3a gene promoter that leads to DNA hypermethylation and drives leukemia cell growth. Suppression of the RNA N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.